6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-001032-72-PT (EUCTR)	23/03/2006	11/11/2005	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step	Parkinson disease	Trade Name: Stalevo Product Code: ELC200 INN or Proposed INN: levodopa /carbidopa /entacapone Trade Name: SINEMET Product Name: sinemet INN or Proposed INN: levodopa /carbidopa	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	424		Portugal;Czech Republic;Italy
2	EUCTR2005-001032-72-CZ (EUCTR)	16/02/2006	12/01/2006	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step		Trade Name: Stalevo 100 mg/25 mg / 200 mg Product Code: ELC200 Trade Name: SINEMET CR Product Name: SINEMET CR	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	424		Portugal;Czech Republic;Italy